Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis To Explore Long-Term "Preferential" Partnerships, CEO Says

Executive Summary

Novartis is interested in exploring preferred partnership arrangements with other pharmaceutical companies that stop short of an outright merger.

You may also be interested in...



Novartis Zelmac DTC Ads To Emphasize Relief Of Abdominal Pain, Bloating

Consumer ads for Novartis Zelmac will emphasize relief of abdominal pain and bloating in addition to constipation, VP and General Manager-U.S. Operations Kurt Graves suggested during an R&D meeting in Basel, Switzerland Dec. 6.

Novartis Zelmac DTC Ads To Emphasize Relief Of Abdominal Pain, Bloating

Consumer ads for Novartis Zelmac will emphasize relief of abdominal pain and bloating in addition to constipation, VP and General Manager-U.S. Operations Kurt Graves suggested during an R&D meeting in Basel, Switzerland Dec. 6.

Novartis, Bristol To Share Zelmac; Novartis Opts For Partnership, Not Merger

Novartis' agreement with Bristol Myers-Squibb to co-promote the irritable bowel syndrome treatment Zelmac (tegaserod) accomplishes one objective of the Swiss company's attempts to grow via a merger in the U.S.

UsernamePublicRestriction

Register

PS037021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel